Wealth & Finance International - Business Awards 2016

www.wealthandfinance-intl.com 5 This consistent success in the enrolment and retention of high numbers of patients at their dedicated clinical research sites has demonstrated that CCBR is able to perform at lower costs per patient. At the country or study level, sponsors and CRO’s can complete clinical research with fewer sites and reduce overall costs of the study delivery. However, although focusing on cost is important, CCBR also recognize that the patient is the priority, and they engage with the patient throughout the clinical trial. From recruitment and enrolment through to the end of the study, CCBR’s dedicated clinical research staff are focused on ensuring that the patient is treated, not only in compliance with the defined protocols, bur with the care and respect they deserve. CCBR project managers are all trained in clinical development and provide a central point of contact for sponsor and CRO clinical operations. From contracting, study start up and ongoing management of clinical site activities, CCBR works hard to reduce the burden of site management for clinical study teams. Dedicated CCBR sites are located, resourced and equipped for the enrolment and treatment of large numbers of patients who are taking part in clinical research. The firm invests in facilities that are strategically located to take advantage of significant patient populations. CCBR’s research centres are dedicated to clinical research and are configured, equipped and staffed to optimize the work of recruiting and treating patients. All CCBR Clinical Research staff are part of the CCBR organization and dedicated to clinical research. Therapeutic Area Specialists, Physicians, Study Nurses, Study Coordinators and Technicians from around the world are recruited, trained and managed to the same high standards which are required of all who work for CCBR. CCBR has developed a quality in processes and procedures that are standardized and validated throughout their network of clinical research centres. Their clinical research is conducted to the same high standards of quality and outstanding compliance across the globe. The firm’s quality driven approach to the standardization of processes, systems and training results in predictable and reliable investigator site performance and world class data integrity. The CCBR ‘blueprint’, as it is known, enables sponsors to bring new drugs faster to market. For more than two decades, CCBR Clinical Research has been participating in the development of new medicines for different diseases including Osteoporosis, Osteoarthritis, Rheumatoid Arthritis, Alzheimer’s Disease, Type 2 Diabetes, Hypertension, Hypercholesterolemia, Gastrointestinal disorders, obesity, respiratory diseases, vaccines, asthma and pain. With Research Centers located around the world, the firm have grown from being a small Danish company to become one of the world´s leading organizations within clinical research. The team are able to contribute to the approval of new and better medicines for the treatment of a wide range of diseases, thanks to the people who throughout the years have volunteered to participate in clinical trials. These medicines are now improving the quality of life for thousands of people all over the world, and moving forward the aim is to continue with this vital work, as Tomas concludes. “Looking ahead, our goals are to ensure high quality site performance, provide high quality patients, provide patients with treatment choices, increase patient engagement and retention, get derailed trials back on track and, ultimately, achieve cost-efficient results. We look forward to the opportunities that achieving these ambitious goals will provide us with in 2017 and beyond.”